Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SRPT message board posts where the ticker symbol SRPT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SRPT SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 8.01
Acc-no: 0001564590-18-023494 (34 Act)  Size: 22 KB
2018-09-24 001-14895
181082612
8-K  Documents Current report, item 8.01
Acc-no: 0001564590-18-023409 (34 Act)  Size: 22 KB
2018-09-21 001-14895
181080520
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-046916 Size: 5 KB
2018-08-16
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-045907 Size: 5 KB
2018-08-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-045905 Size: 5 KB
2018-08-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-045903 Size: 5 KB
2018-08-08
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-020534 (34 Act)  Size: 11 MB
2018-08-08 001-14895
181001915
8-K  Documents Current report, item 5.02
Acc-no: 0001564590-18-018526 (34 Act)  Size: 24 KB
2018-08-01 001-14895
18985664
8-K  Documents Current report, item 8.01
Acc-no: 0001564590-18-017453 (34 Act)  Size: 23 KB
2018-07-26 001-14895
18969529
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-042890 Size: 19 KB
2018-07-17
More SRPT SEC Filings


Related news from
Tue, 25 Sep 2018
14:44:02 +0000
FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program
The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.
Mon, 24 Sep 2018
20:43:08 +0000
CHMP Reconfirms Negative Opinion for Sarepta's Exondys
The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
Mon, 24 Sep 2018
12:19:00 +0000
Sarepta stock rises after FDA lifts clinical hold on gene therapy program
Sarepta Therapeutics Inc. shares rose 1.6% in Monday premarket trade after the U.S. Food and Drug Administration lifted a clinical hold from the company's gene therapy for the rare disease Duchenne muscular dystrophy. The FDA had previously placed the hold on July 25 "due to the presence of a trace amount of DNA fragment in research-grade third-party supplied plasmid," Sarepta previously said. Sarepta made and submitted an "action plan" to the FDA, which includes an audit of the plasmid supplier and Sarepta committing to using plasmid made according to the FDA's "good manufacturing practices" in the future. The company hopes to get a registration trial for the gene therapy program started by the end of the year, Chief Executive Doug Ingram said. Sarepta shares have surged 5.2% over the last three months, compared with a 6.3% rise in the S&P 500 and a 8.8% rise in the Dow Jones Industrial Average .
Mon, 24 Sep 2018
11:00:00 +0000
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program. Sarepta previously announced on July 25, 2018, that the FDA placed the program on clinical hold due to the presence of trace amounts of DNA fragment in research-grade third-party supplied plasmid in a manufacturing lot.
Fri, 21 Sep 2018
16:15:32 +0000
What Do Analysts Recommend for Sage in September?
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company, is developing medicines for the treatment of life-altering central nervous system disorders like major depressive disorder, Parkinson’s disease, postpartum depression, and others.
Fri, 21 Sep 2018
16:01:59 +0000
Sarepta investors, analysts shrug off E.U. setback for Duchenne drug
European approval of the drug "is a matter of 'when' not 'if,'" according to one analyst note.
Fri, 21 Sep 2018
10:48:00 +0000
Sarepta expected, but is disappointed by European regulators decision on DMD treatment
Sarepta Therapeutics Inc. said Friday that the Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (EMA) upheld the negative opinion for the company's conditional marketing application for eteplirsen, for the treatment of Duchenne muscular dystrophy. The stock was still inactive in premarket trade. "While largely anticipated, we are disappointed with the outcome of the CHMP re-examination and firmly believe that eteplirsen should be made available to patients in Europe, as it is in the United States," said Chief Executive Doug Ingram. The company had received the negative opinion on May 31, after which it requested a re-examination of the opinion. The stock had nearly tripled year to date (up 175%) through Thursday, while the S&P 500 has gained 9.6%.
Fri, 21 Sep 2018
10:30:00 +0000
Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has confirmed its 31 May 2018 negative opinion for a Conditional Marketing Application for eteplirsen. Eteplirsen is designed to treat approximately 13% of the Duchenne muscular dystrophy community who have genetic mutations amenable to exon 51 skipping.
Thu, 20 Sep 2018
12:04:24 +0000
See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Fri, 14 Sep 2018
18:54:45 +0000
What Solid Biosciences’ Valuation Trend Indicates
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Fri, 14 Sep 2018
18:05:02 +0000
How’s PTC Therapeutics Positioned in September?
In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.
Fri, 14 Sep 2018
16:30:40 +0000
Analyzing PTC Therapeutics’ Performance in September
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Fri, 14 Sep 2018
14:42:05 +0000
Sarepta Therapeutics Has Returned 169.97% Year-to-Date
Sarepta Therapeutics (SRPT) has returned 169.97% YTD (year-to-date). In the second quarter, it reported EPS of -$0.43, surpassing the consensus estimate by $0.46. EXONDYS 51 sales were $73.5 million in the quarter, which is a YoY (year-over-year) rise of 110%. Wall Street analysts have projected a 12-month consensus target price of $188.58, which is a 25.54% rise over its closing price on September 13. By the end of 2018, Sarepta Therapeutics plans to submit a rolling NDA (New Drug Application) to the FDA for golodirsen, an investigational phosphorodiamidate Morpholino oligomer (or PMO) therapy, in Duchenne muscular dystrophy (or DMD) due to deletions in the DMD gene related to exon 53 skipping.
Thu, 13 Sep 2018
18:03:50 +0000
Exondys 51 Growth Bodes Well for Sarepta’s Top Line
Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on developing unique RNA-targeted therapeutics, gene therapy, and other genetic products targeted for rare neuromuscular diseases. Sarepta’s first product on the market, Exondys 51 (eteplirsen), is indicated for treating Duchenne muscular dystrophy (or DMD). In June, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a negative opinion for eteplirsen.
Thu, 13 Sep 2018
18:03:50 +0000
What Sarepta Therapeutics’ Valuation Trend Indicates
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
Thu, 13 Sep 2018
18:03:46 +0000
Audentes Therapeutics’ Promising Product Pipeline
Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.
Wed, 12 Sep 2018
17:10:00 +0000
Corrective Action in This Market Is Often Quite Hidden
The indices are being jerked around on some news headlines today. These headlines trigger very obvious "buy" algorithms that took the indices into positive territory. Within about 30 minutes the move was totally reversed but some buyers have remained and have the indices off the lows.
Tue, 11 Sep 2018
23:43:33 +0000
Why Sarepta Therapeutics, Inc. Stock Jumped 18.8% Higher in August
The company's only drug, Exondys 51, is selling well, but investors should be watching the pipeline.
Mon, 10 Sep 2018
18:17:00 +0000
Six Biotechnology Names on My Watch List
The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.
Fri, 07 Sep 2018
21:05:00 +0000
Sarepta Therapeutics CEO has a 'big ambition' for muscular dystrophy gene therapy
Sarepta Therapeutics CEO Doug Ingram wants the company to start giving its Duchenne muscular dystrophy gene therapy to children in the approval trial by the end of this year. "We have a big ambition to potentially be to the community within two years thereafter," he says. Sarepta Therapeutics CEO Doug Ingram told CNBC on Friday he has a "big ambition" to get the company's Duchenne muscular dystrophy gene therapy to patients as quickly as possible.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is a great group of very smart, sophisticated investors. We have several professionals on board managing millions of dollars, and "average Joe" investors that beat the pants off of Wall Street professionals year in and year out. ValueForum will expose you to a wealth of ideas and sectors, and keep you ahead of the curve." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards